Document Detail


Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice.
MedLine Citation:
PMID:  18852082     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A correct histological diagnosis, careful staging and detection of tumour response to treatment are all crucial in the management of sarcomas. Imaging is important in all of these stages. Sarcomas have distinct biological and treatment-related features posing challenges for imaging. For example, size measurements may not adequately reflect response rates. Techniques which can measure tissue function rather than generate merely anatomical data such as positron emission tomography (PET) are rapidly gaining interest. We discuss the importance of imaging in different stages of patient management, emphasising the unique characteristics of sarcoma. Furthermore, we discuss the potential of PET for the various indications, focussing on therapy evaluation.
Authors:
A C M van de Luijtgaarden; J W J de Rooy; L F de Geus-Oei; W T A van der Graaf; W J G Oyen
Publication Detail:
Type:  Journal Article; Review     Date:  2008-10-04
Journal Detail:
Title:  Cancer imaging : the official publication of the International Cancer Imaging Society     Volume:  8 Spec No A     ISSN:  1470-7330     ISO Abbreviation:  Cancer Imaging     Publication Date:  2008  
Date Detail:
Created Date:  2008-10-14     Completed Date:  2008-11-14     Revised Date:  2010-10-05    
Medline Journal Info:
Nlm Unique ID:  101172931     Medline TA:  Cancer Imaging     Country:  England    
Other Details:
Languages:  eng     Pagination:  S61-8     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone Neoplasms / radionuclide imaging
Fluorodeoxyglucose F18 / diagnostic use
Gastrointestinal Stromal Tumors / radionuclide imaging
Humans
Magnetic Resonance Imaging
Neoplasm Staging
Positron-Emission Tomography
Sarcoma / pathology,  radionuclide imaging*,  therapy
Chemical
Reg. No./Substance:
63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  PET/CT imaging in the diagnosis, staging, and follow-up of colorectal cancer.
Next Document:  Critical questions in the imaging of colorectal hepatic metastases.